摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-3,4-dihydroquinazoline | 75191-78-5

中文名称
——
中文别名
——
英文名称
2-amino-3,4-dihydroquinazoline
英文别名
1,4-Dihydroquinazolin-2-amine
2-amino-3,4-dihydroquinazoline化学式
CAS
75191-78-5
化学式
C8H9N3
mdl
——
分子量
147.18
InChiKey
GQRRWNLARRRPRY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    214-216 °C(Solv: isopropanol (67-63-0))
  • 沸点:
    292.9±43.0 °C(Predicted)
  • 密度:
    1.33±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    50.4
  • 氢给体数:
    2
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2-amino-3,4-dihydroquinazoline三乙胺 作用下, 以 甲醇氯仿 为溶剂, 反应 3.5h, 生成 2-acetylamino-3,4-dihydroquinazoline
    参考文献:
    名称:
    环状胍。九。合成2-氨基-3,4-二氢喹唑啉作为血小板凝集抑制剂。
    摘要:
    合成了一系列含有苯基或苯甲基取代的2-氨基-3,4-二氢喹唑啉及其相关化合物。这些化合物在体外和体内对大鼠血小板胶原和ADP诱导的聚集具有抑制活性,其中一类3-苄基取代的衍生物表现出较强的活性。相关结构与活性的关系进行了探讨。
    DOI:
    10.1248/cpb.28.1357
  • 作为产物:
    描述:
    3,4-dihydro-1H-quinazoline-2-thione 在 ammonium acetate 作用下, 以 乙醇 为溶剂, 反应 5.0h, 生成 2-amino-3,4-dihydroquinazoline
    参考文献:
    名称:
    Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR
    摘要:
    Basic molecular building blocks such as benzene rings, amidines, guanidines, and amino groups have been combined in a systematic way to generate ligand candidates for HIV-1 TAR RNA. Ranking of the resulting compounds was achieved in a fluorimetric Tat-TAR competition assay. Although simple molecules such as phenylguanidine are inactive, few iteration steps led to a set of ligands with IC50 values ranging from 40 to 150 mu M. 1,7-Diaminoisoquinoline 17 and 2,4,6-triaminoquinazoline 22 have been further characterized by NMR titrations with TAR RNA. Compound 22 is bound to TAR at two high affinity sites and shows slow exchange between the free ligand and the RNA complex. These results encourage investigations of dimeric ligands built from two copies of compound 22 or related heterocycles. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.11.004
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE (BACE)<br/>[FR] NOUVEAUX DERIVES DE 2-AMINO-QUINAZOLINE UTILES EN TANT QU'INHIBITEURS DE LA $G(B)-SECRETASE (BACE)
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2006017844A1
    公开(公告)日:2006-02-16
    The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer’s disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.
    本发明涉及新颖的2-氨基-3,4-二氢喹唑啉衍生物,包含它们的药物组合物以及它们在治疗阿尔茨海默病(AD)和相关疾病中的用途。本发明的化合物是β-分泌酶的抑制剂,也被称为β-位点裂解酶和BACE。
  • [EN] 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE)<br/>[FR] DERIVES DE 2-AMINO-QUINAZOLINE UTILES EN TANT QU'INHIBITEURS DE B-SECRETASE (BACE)
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2006024932A1
    公开(公告)日:2006-03-09
    The present invention is directed to novel 2-amino-3,4-dihydro­quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ß-secretase, also known as ß-site cleaving enzyme and BACE.
    本发明涉及新型2-氨基-3,4-二氢喹唑啉衍生物,包含它们的药物组合物以及其在治疗阿尔茨海默病(AD)和相关疾病中的用途。该发明的化合物是ß-分泌酶抑制剂,也称为ß-位点裂解酶和BACE。
  • HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
    申请人:Amberg Wilhelm
    公开号:US20100041698A1
    公开(公告)日:2010-02-18
    The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
    该发明涉及一般式(I)的化合物,其相应的对映体、异构体和/或互变异构体形式,以及其药学上可接受的盐和所述化合物的前药。该发明还涉及将所述化合物用作5-HT5受体的结合伙伴,用于治疗受5-HT5受体活性调节的疾病,特别是用于治疗神经退行性和神经精神障碍以及相关的症状和功能障碍。
  • 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds
    申请人:——
    公开号:US20020032262A1
    公开(公告)日:2002-03-14
    A solid support template for the preparation of highly functionalized heterocycle compounds of the formula; 1
    一种固体支撑模板,用于制备公式为1的高度功能化杂环化合物。
  • Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE)
    申请人:Bischoff Paul Francois
    公开号:US20060178383A1
    公开(公告)日:2006-08-10
    The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.
    本发明涉及新型2-氨基-3,4-二氢喹唑啉衍生物、含有它们的制药组合物以及它们在治疗阿尔茨海默病(AD)和相关疾病中的应用。本发明的化合物是β-秘鲁酶的抑制剂,也称为β-位点裂解酶和BACE。
查看更多